Soligenix announced that new supportive trial data for its HyBryte treatment for cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026, ahead of the American Academy of Dermatology Annual Meeting. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor, supporting HyBryte's potential as a therapeutic option for CTCL.
This development is significant because cutaneous T-cell lymphoma is a rare cancer with limited treatment options, and HyBryte represents a novel photodynamic therapy utilizing safe visible light. The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, with successful completion of a second Phase 3 study paving the way for regulatory approvals worldwide. The comparative analysis against Valchlor, an existing treatment, provides important context for clinicians evaluating therapeutic options for their patients.
The implications of this announcement extend to patients, healthcare providers, and the pharmaceutical industry. For patients with CTCL, the availability of additional treatment options could mean improved outcomes and quality of life. The long-term treatment data being presented addresses an important consideration in chronic conditions like CTCL, where sustained efficacy and safety profiles are critical. For the dermatology community, the data presentation at the USCLC Workshop provides evidence-based information to guide treatment decisions.
From an industry perspective, Soligenix's progress with HyBryte demonstrates continued innovation in addressing unmet medical needs in rare diseases. The company's broader development pipeline includes expansion of synthetic hypericin into psoriasis, dusquetide for inflammatory diseases including oral mucositis in head and neck cancer, and development programs in Behcet's Disease. The Public Health Solutions business segment includes vaccine candidates for ricin toxin, filoviruses, and COVID-19, incorporating proprietary heat stabilization technology supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases.
The full press release is available at https://ibn.fm/iTepg, and the latest news and updates relating to Soligenix are available in the company's newsroom at https://ibn.fm/SNGX. The company notes that certain statements are forward-looking and subject to risks and uncertainties, with full terms of use and disclaimers available at http://IBN.fm/Disclaimer.
